Amyloid Aggregation Inhibitory Mechanism of Arginine-rich D-peptides

It is widely believed that Alzheimer's disease pathogenesis is driven by the production and deposition of the amyloid-peptide (A) in the brain. In this study, we employ a combination of in silico and in vitro approaches to investigate the inhibitory properties of selected arginine-rich D-enantiomeric peptides (D-peptides) against amyloid aggregation. The D-peptides include D3, a 12-residue peptide with anti-amyloid potencies demonstrated in vitro and in vivo, RD2, a scrambled sequence of D3, as well as truncated RD2 variants. Using a global optimization method together with binding free energy calculations followed by molecular dynamics simulations, we perform a detailed analysis of D-peptide binding to A monomer and a fibrillar A structure. Results obtained from both molecular simulations and surface plasmon resonance experiments reveal a strong binding of D3 and RD2 to A, leading to a significant reduction in the amount of structures in both monomer and fibril, which was also demonstrated in Thioflavin T assays. The binding of the D-peptides to A is driven by electrostatic interactions, mostly involving the D-arginine residues and Glu11, Glu22 and Asp23 of A. Furthermore, we show that the anti-amyloid activities of the D-peptides depend on the length and sequence of the Dpeptide, its ability to form multiple weak hydrophobic interactions with A, as well as the A oligomer size.